SEC Comment Letter 0000000000-24-006281 to KAZIA THERAPEUTICS LTD (KZIA) (CIK 0001075880) (KZIA)
KAZIA THERAPEUTICS LTD (KZIA) (CIK 0001075880)
Date: May 31, 2024 · CIK: 0001075880 · Accession: 0000000000-24-006281
AI Filing Summary & Sentiment
File numbers found in text: 333-279773
Letter
United States securities and exchange commission logo May 31, 2024 John Friend Chief Executive Officer Kazia Therapeutics Limited 300 Barangaroo Avenue Sydney, NSW, 2000, Australia Re:Kazia Therapeutics Limited Registration Statement on Form F-1 Filed May 29, 2024 File No. 333-279773 Dear John Friend: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jimmy McNamara at 202-551-7349 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Robert E. Puopolo
Show Raw Text
United States securities and exchange commission logo
May 31, 2024
John Friend
Chief Executive Officer
Kazia Therapeutics Limited
300 Barangaroo Avenue
Sydney, NSW, 2000, Australia
Re:Kazia Therapeutics Limited
Registration Statement on Form F-1
Filed May 29, 2024
File No. 333-279773
Dear John Friend:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jimmy McNamara at 202-551-7349 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Robert E. Puopolo